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Abstract The human mdrl gene encodes a transmembrane glycoprotein the over-expression f which is associated with development ofmultidrug 
resistance in human tumor cells. A negative modulation of human mdrt has been attempted via a 27-met unmodified triple helix-forming oligonu- 
cleotide, named 1 D, targeted to a homopurine sequence in the coding region of the gene. By administering 10/zM of 1D we could find a significant 
reduction i  MDR1 mRNA levels in the human drug-resistant cell line CEM-VLBI00. This effect appears to be specific and due to a transient block 
of RNA polymerase mediated by triple helix formation. 
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1. Introduction 
Studies on nucleic acid triple helices date back more than 30 
years [1], but only recently has interest in triple helix DNA 
structures increased they represent potential biological reagents 
for chromosome mapping and gene analysis [2]. These unusual 
structures are formed by the interaction of a homopyr/ho- 
mopur sequence with the major groove ofa homopur :homopyr 
Watson-Crick (W-C) target via Hoogsteen or 'reverse' 
Hoogsteen hydrogen bonds. Essentially, three major triple helix 
structural motives can be recognized: the acidic pH-dependent 
pyrimidine one based on C+-GC. T-AT triplets, in which the 
third strand is parallel to the homopurinic W-C sequence; the 
pH-independent purine and mixed purine/pyrimidine ones 
based on G-GC, A-AT and G-GC, T-AT triplets, respectively, 
in which the third strand is orientated antiparallel or parallel 
with respect o the homopurinic W-C sequence depending on 
its base composition [3]. The potential selective interaction 
within megabase DNA has suggested the possibility of ex- 
ogenously modulating ene expression by intermolecular t i- 
plex formation [5,6]. Many in vitro experiments have demon- 
strated that triple helix-forming oligodeoxyribonucleotides 
(ODNs) can selectively inhibit gene transcription, either by 
preventing transcription factor binding to promoters [6,7] or by 
blocking transcription elongation [8,9]. This has led to consid- 
eration of the triple helix 'anti-gene' strategy as a new therapeu- 
tic approach to selectively suppress unwanted gene expression 
in vivo. The apparent limitation of triplex targeting in vivo has 
been overcome following evidence that relatively long stretches 
of homopurine:homopyrimidine sequences are often present 
within the eukaryotic genome [10] and that their frequency 
increases 3.54 times in higher eukaryotes [11]. In human cells, 
transcription i hibition at the genomic level by purinic triple 
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tide. 
helix-forming ODNs has been described for c-myc [12] and 
IL2R~ [13] genes. 
The intrinsic or acquired pleiotropic resistance to drugs, 
called multidrug-resistance (MDR), is one of the major obsta- 
cles in cancer treatment [14]. In human tumors, the MDR 
phenomenon is often associated with the over-expression, and 
sometimes the amplification [15-17] of the mdrl gene encoding 
a constitutive transmembrane glycoprotein (P-gp). Although 
the precise physiological function of P-gp is still unknown, in 
cancer-resistant cells it is responsible for a rapid energy-de- 
pendent efflux of many structurally and funcionally unrelated 
anti-tumor chemicals [18]. Current strategies to circumvent 
drug resistance involve the administration of toxic agents, 
which have adverse side effects [14]. Although at the initial 
stage, studies in mice seem to have demonstrated that admini- 
stration of ODNs can reach therapeutic values in organs and 
can be well tolerated [19-21]. 
We tried to inhibit human mdrl gene expression in MDR 
cells by intermolecular triple helix formation and demonstrate 
that a natural, unmodified triple helix-forming ODN can signif- 
icantly reduce MDR1 mRNA levels in a MDR cell line. 
2. Materials and methods 
2.1. Oligonucleotide synthesis and purification 
ODNs or modified ODNs were synthesized on an automated DNA 
synthesizer Model 380 B (Applied Biosystem) by the phosphoramidite 
method, according to standard procedures (1/zmol scale), and purified 
by FPLC on an anionic-exchange MONO Q HR 5/5 column (Pharma- 
cia) utilizing an ammonium bicarbonate gradient. The purity of ODNs 
was controlled on a 20% acrylamide/7 M urea gel under denaturing 
conditions. 
2.2. Triple helix detection i vitro 
Optical melting curves were performed at 260 nm on a Cary spectro- 
photometer model 220 (Varian) equipped with a Tandy 102 tempera- 
ture programmer, connected to a Haake K.F3 thermostat. Equimolar 
concentrations ofODN and its corresponding synthetic target duplex 
were mixed in 75 mM Tris-HC1, pH 7.2, containing 75 mM NaC1, 10 
mM MgCI:, 2 mM spermine, and heated at a rate of 0.4°C/rain from 
5 to 80 °C. 
Triplex gel-retardation assays were performed with 5' 32P-labeled 
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ODN prepared by standard procedures with T4 polynucleotide kinase 
(Promega). ODN and ODN annealed with its a2P-labelled uplex 
(ODN/duplex, 100/1) in 75 mM Tris-HCl, pH 7.2, containing 10 mM 
MgCI2, 75 mM NaC1 and 2 mM spermine, were loaded on 15% 
acrylamide non-denaturing gels and electrophoresis performed at 20°C 
for 2 h, utilizing 0.1 M sodium phosphate buffer, pH 7.2, at 6 V/cm. 
Triple helix formation was identified as a band migrating slower than 
that of the duplex. 
2.3. Cell cultures and ODN administration 
A human MDR cell line of leukemic T-lymphoblasts (CEM- 
VLB100) [22] was cultured in RPMI 1640 containing 10% fetal calf 
serum, 2 mM L-GIn, 100 U/ml penicillin and 100/zg/ml streptomycin 
(Seromed; Biochrom KG). The MDR phenotype was mantained with 
50 ng/ml vinblastine. Prior to administering ODN, the cells were cul- 
tured in drug-free medium for 24 h. For RNA quantitation experiments 
5 x 106 cells were seeded in complete medium and one dose of ODNs, 
ranging from 2.5 to 10/tM, were supplied in a final volume of 10 ml. 
To quantify cell ODN uptake, 2 x l0 s cells/ml were seeded in 96-well 
microtiter plates and incubated at 37°C with 15/zM ODN containing 
trace amounts of 5' 32p-labeled ODN purified by Sephadex G25 exclu- 
sion chromatography to remove unincorporated label. The medium 
was then discarded, the cells rinsed twice with PBS, and lysed with 50 
/.tl of HIRT solution (10 mM Tris-HC1, pH 7.5, 10 mM EDTA, 0.6% 
SDS). The total radioactivity was evaluated as scintillation counts 
(fl-Counter LS 1801; Beckman). 
To detect he presence of undegraded ODN in living cells, 0.5 x 106 
CEM-VLBI00 cells were cultured in 1 ml of complete medium. The 
cells were exposed to 20/~M ODN containing trace amounts of 5' 
32P-labeled ODN at 370C for variable times. The cells were collected 
by centrifugation at 400 × g for 5 min, rinsed once with 0.2 M Gly/ 
NaOH, pH 4.0, twice with physiological saline solution, and then dis- 
rupted with 0.2% SDS/4 M urea. The samples were then loaded onto 
15% acrylamide/7 M urea gels, electrophoresed for2 h at 8 V/cm, 420C, 
and the gels then exposed to Kodak XAR-OMAT film. 
2.4. Total RNA extraction and quantitation 
Total RNA was extracted from the cells as described by 
Chomczynsky and Sacchi [23]. The RNA quality was evaluated by 
ribosomal band integrity in 1% agarose/formaldehyde gels. From 10 to 
20 gg of total RNA were transferred on to nylon filters (Magna charge, 
MSI) with l0 x SSC (1.5 M NaC1, 0.15 M sodium citrate, pH 7.0). 
Northern blot filters were hybridized with pDHR5A MDR1 cDNA [24] 
at 65°C in Church solution (0.5 M sodium phosphate buffer, pH 7.2, 
containing 7% SDS and 1 mM EDTA) and specific probe recognition 
was assured by high stringency conditions of temperature and rinsing 
(from 5 × to 0.1 × SSC, 65°C). The same filters were then rehybridized 
with human GPDH or mouse fl-actin cDNA probes at 58°C, rinsing 
the filters from 5 x to 1 × SSC at the same temperature. The filters were 
exposed to Kodak XAR-OMAT films. All probes were labeled with 
[ct-32p]dCTP by the random hexamer priming method. The quality of 
detection of MDR1 mRNA was assured by the absence of signals in 
the line corresponding to sensitive non-MDR CCRF-CEM cells (data 
not shown). 
Autoradiogram band intensities were quantified by densitometric 
laser scanning (Ultroscan XL, Pharmacia). Laser scan densitometric 
values of MDR1 mRNA of treated cells were normalized to that of 
control GPDH mRNA and expressed as % difference with respect o 
M DR 1/GPDH normalized values of untreated or control ODN-treated 
samples. Comparison of mRNA ratios were made only between sam- 
ples on the same filter and which had been probed under identical 
conditions. 
3. Results and discussion 
Within the genomic sequence of the human mdrl gene [25] 
we identified a homopurinic stretch in exon 3 of  the coding 
region from position 69 to 93. We synthesized a natural 
phosphodiester 27-met ODN,  named 1D, orientated parallel 
with respect o the homopurine W-C strand, and its antiparallel 
sequence, named 1E. The ODNs were also designed to recog- 
nize the two last conserved bases of intron 2 and to establish 
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Fig. 1. (A) Sequence of the putative mdrl and the triplex-forming region 
of ODN 1D. Bases in the 1D sequence indicated with arrowheads 
correspond to mismatch sites. (B) In vitro triple helix formation demon- 
strated by thermal denaturation curves: 4 nmol of the 35 bp synthetic 
target strands in 2 ml were annealed alone or with equimolar concentra- 
tions of 1D or 1E (antiparallel with respect o 1D) as described in 
section 2. The optical values obtained at 260 nm for the duplex and the 
triplex are plotted as a function of temperature ((3, duplex alone; 
o, duplex + 1D; &, duplex + 1E). (C) Triplex gel-retardation assay. 0.1 
gM of synthetic target, containing trace amounts of labeled uplex, was 
annealed with 10 gM of 1D or lE (antiparallel with respect o lD) as 
described in section 2. All samples were heated at 90°C and then 
allowed to cool at room temperature for at least 2 h prior to their 
loading into a non-denaturing gel (a, duplex; b, duplex + 1 E; c, du- 
plex + lD). 
T-AT and G-GC triplets (Fig. 1A). In thermal denaturation 
experiments performed at pH 7.2, 1D in the presence of  the 
corresponding 35 bp synthetic duplex at equimolar concentra- 
tions was able to produce a biphasic profile, characteristic of 
third strand dissociation from a W-C duplex (Fig. 1B). In fact, 
since the triple helix has a lower stability than the correspond- 
ing duplex, in thermal denaturation experiments the dissocia- 
tion of the triplex precedes duplex melting so that a biphasic 
curve results [26,27]. In contrast, addition of the antiparallel 
sequence IE to the W-C duplex did not result in a triple helix 
dissociation curve, but only in an increase in W-C melting 
optical values due to the absorbance contribution of the single 
strand. Thus, as expected, the preferred orientation of  the third 
strand is parallel with respect o the homopurinic W-C strand, 
according to its prevalent pyrimidinic omposition [28]. More- 
over, although 1D showed slow kinetics of  association and 
partial stability in a triplex form at 37°C, it was able to produce 
a retardation in the gel electrophoresis migration of  the duplex, 
whereas 1E did not significantly change duplex migration (Fig. 
1C). 
These data suggested that l D might possess ufficient duplex 
sequence selectivity under physiological conditions to be a can- 
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Fig. 2. (A) Cell ODN uptake. 2 x 104 CEM-VLB100 cells were incu- 
bated at 37°C for the indicated times with 15 pM ID containing trace 
amounts of labeled strand. Total radioactivity ofwhole-cell lysates was 
evaluated by scintillation counts. The specific activity of the culture 
medium was determined for each sample and did not change over the 
course of the experiments (1,800,000 cpm/well). (B) Recovery of full- 
length ODN from the cells. 0.5 x 106 CEM-VLB100 cells were incu- 
bated at 37°C for the indicated times with 20/tM 1D containing trace 
amounts of labeled strand. Cellular lysate was loaded on a 15% 
acrylamide denaturing el. Labeled 1D was loaded under the same 
conditions to mark undegraded ODN migration (arrowhead). 
didate for inhibition of mdr l  gene transcription i  human 
MDR cell lines. 
The cell uptake of ODN is now well documented. Depending 
on the ODN extracellular concentration, they may enter the 
cells either by specific absorptive endocytosis or by pinocytosis 
[29-31]. Although natural phosphodiester ODNs undergo a 
rapid extra-intracellular degradation [32,33], they can partially 
persist in the cell and rapidly reach the nucleus [12,34,35]. We 
demonstrated ODN cellular uptake in CEM-VLB 100 by expos- 
ing the cells to 5'-labeled ODN. As illustrated in Fig. 2A, 
increasing amounts of cell-associated 1D was detected uring 
the time of incubation. Similar results were obtained utilizing 
an ODN of the same length but with a different base composi- 
tion (data not shown). Although with this labeling method the 
loss of labeled 32p from the intact oligomer by cell-associated 
phosphatase activity can not be avoided, we calculated that 
approximately 0.1% of the total ID supplied was associated 
with whole cells after 1 h of incubation at 37°C. Furthermore, 
we also demonstrated that by removing cell surface-bound 
ODN with acidic rinsing [35], undegraded 1D may be recovered 
from living cells after at least 4 h incubation at 37°C (Fig. 2B). 
In order to investigate he effect of the triple helix on mdr l  
transcription we administered one dose of 1D ranging from 2.5 
to 10/.tM to CEM-VLB100 cells. Total RNA was extracted 
after 24 h incubation to avoid interference measurements due 
to a possible increase in MDR1 mRNA lifetime detected in 
MDR cell lines [36]. The Northern blot analyses, illustrated in 
Fig. 3A, demonstrate a significant, specific and dose-dependent 
reduction of MDR1 mRNA levels in 1D-treated cells with 
respect o untreated ones, by comparing the signals obtained 
from rehybridization f the same filters with the GPDH control 
probe. The same results were obtained utilizing a fl-actin con- 
trol probe (data not shown). Treatments with the inefficient 
triple helix-forming ODN 1E did not result in a variation in 
MDR1 mRNA levels with respect o untreated cells (Fig. 3B). 
Quantitation from seven independent experiments performed 
with 10 pM ODNs indicated a 46 _+ 16% (S.D.) reduction in 
MDR1 mRNA in cells treated with 1D triple helix-forming 
ODN, with respect o untreated or 1E-treated controls. 
Although sequence, orientation and type of administration 
of 1D seem incompatible with an antisense effect, we investi- 
gated the effect of cellular administration f a fully modified 
phosphorothioate 1D (1Ds). In fact, phosphorothioated ODNs 
are resistant to exo-endonuclease digestion and are thus suita- 
ble for antisense activity, retaining the ability to hybridize with 
mRNA [33,37]. However, phosphorothioate modification re- 
duces the triplex stability and can completely impair triple helix 
formation [38,39]. In fact, the melting curve of 1Ds in the 
presence of its duplex W-C did not give the characteristic bipha- 
sic profile (Fig. 4A). As expected, considering the inability of 
1Ds to form a triple helix, we did not detect a variation in 
MDR1 mRNA levels in 1Ds-treated CEM-VLB100 cells (Fig. 
4B). For this reason we consider a potential antisense effect of 
ID unlikely. 
Taken together, these results eem to indicate that the natural 
unmodified triple helix-forming ODN 1D is able to inhibit, at 
least partially, MDR1 mRNA transcription i vivo. Since the 
DNA target is located in the coding region of the gene, we 
suggest that 1D may interfere with RNA polymerase activity. 
4. Conclusions 
ODN-directed intermolecular triple helix formation isone of 
the newest biotechnological approachies to allow site-specific 
targeting within megabase DNA. Small quantities of ODNs 
escaping intracellular degradation and persisting in to the nu- 
NT 2~ 5.0 10 
MDR 
GPDH 
B NT 1E ID  
MDR 
~ ~  GPI~I 
Fig. 3. MDR1 mRNA reduction by ID. (A) Northern blot of total 
RNA extracted from 5 × 106 CEM-VLB100 cells, untreated (NT) or 
treated with 2.5-10/.tM 1D as described insection 2. Autoradiography 
of the filter rehybridized with the GPDH control probe is also illus- 
trated. (B) Northern blot of total RNA extracted from 5 × 106 CEM- 
VLB100 untreated (NT) or treated with 10 ~M of 1D or IE. The 
autoradiogram of the filter rehybridized with the GPDH control probe 
is also included. 
B. Scaggiante t al./ FEBS Letters 352 (1994) 380-384 383 
0,5' 
0,4" 
2.O ,.O 6'o 8'0 
Temperature (:C) 
ID IDs NT 
B 
MDR 
GPDH 
Fig. 4. Effect of fully phosphorothioated 1D (1Ds) on MDR i mRNA 
levels. (A) Thermal denaturation curve. 4 nmol of the 35 bp synthetic 
duplex in 2 ml were annealed alone or with equimolar concentrations 
of 1Ds, as described in section 2. Absorbances at 260 nm of duplex 
alone and of duplex in the presence of 1Ds, are reported as a function 
of temperature (©, duplex; e, duplex + 1Ds). (B) Northern blot of total 
RNA extracted from 5 x 104 CEM-VLB100 cells, untreated (NT) or 
treated with 10/JM of 1Ds or 1D, as described in section 2. Rehybridi- 
zation of the filter with the control GPDH probe is illustrated. 
cleus [12,34] may be sufficient o inhibit mRNA transcription. 
In fact, the target at the DNA level is lower than at the mRNA 
level, being the messenger continuously supplied by the tran- 
scription process. 
Our results demonstrate he potential of a natural unmodi- 
fied pyrimidine-rich triple helix-forming ODN to specifically 
reduce MDR1 mRNA levels in MDR cells. The specificity of 
1D in recognizing its target is supported by the absence of an 
antisense ffect and by the lack of effect on MDR1 mRNA 
levels in cells treated with an ODN with the same sequence but 
opposite orientation, unable to form a triple helix in vitro. 
Although we were unable to detect MDR1 truncated tran- 
scripts, since the probe recognizes a part of the gene down- 
stream of the target exon 3 from 1178 to 2561 bp [25], we 
suspect hat the triple helix can physically block the movement 
of RNA polymerase on the template DNA [8,41]. 
The partial reduction of MDR1 mRNA levels observed 
under our conditions might be related to the passive dissocia- 
tion of 1D from the duplex, as seen in in vitro triple helix 
kinetics. In fact, melting curves we calculated that at 37°C only 
20% of 1D was associated in a triplex form. Furthermore, we 
can not rule out the possibility that enzymatically susceptible 
unmodified ODN, reaching the nucleus intact may be insuffi- 
cient for complexing all copies of the mdrl  gene present in this 
drug-selected cell line [42]. 
The role of 1D in reducing MDR1 mRNA in MDR cell lines, 
associated to a low toxicity in animal models [20,21], could 
provide an interesting strategy for further investigation for the 
control of MDR cancer cells with respect to drug-resistant 
human tumor treatments. 
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